Your AI-Trained Oncology Knowledge Connection!

Naifa L. Busaidy, MD, FACP, FACE

home / authors / naifa-l-busaidy-md

Articles

Novel Treatment Advances in Differentiated Thyroid Cancer

Lori J. Wirth, MD;Marcia Brose, MD, PhD, FASCO;Naifa L. Busaidy, MD, FACP, FACE;Maria E. Cabanillas, MD;Giuseppe Barbesino, MD

February 3rd 2022

An overview of therapies in the pipeline for differentiated thyroid cancer and their potential effect on clinical decision-making.

Second-Line Treatment Approaches for DTC

Lori J. Wirth, MD;Naifa L. Busaidy, MD, FACP, FACE;Marcia Brose, MD, PhD, FASCO

February 3rd 2022

Naifa L. Busaidy, MD, FACP, FACE, recognizes the importance of reassessing patients prior to considering a second-line therapy for differentiated thyroid cancer.

Systemic Therapy Algorithms in DTC

Lori J. Wirth, MD;Marcia Brose, MD, PhD, FASCO;Maria E. Cabanillas, MD;Naifa L. Busaidy, MD, FACP, FACE

January 28th 2022

Considerations regarding approaches to sequencing therapies for differentiated thyroid cancer.

Dr. Busaidy on the Association Between THST and Improved Outcomes

Naifa L. Busaidy, MD, FACP, FACE

October 31st 2014

Naifa L. Busaidy, MD, associate professor, MD Anderson Cancer Center, discusses the results of a cooperative study that investigated the association between long-term thyroid hormone suppression therapy and improved outcomes in patients.